HRP20030490A2 - Repinotan kit - Google Patents

Repinotan kit Download PDF

Info

Publication number
HRP20030490A2
HRP20030490A2 HR20030490A HRP20030490A HRP20030490A2 HR P20030490 A2 HRP20030490 A2 HR P20030490A2 HR 20030490 A HR20030490 A HR 20030490A HR P20030490 A HRP20030490 A HR P20030490A HR P20030490 A2 HRP20030490 A2 HR P20030490A2
Authority
HR
Croatia
Prior art keywords
acid
repinotan
solution
preparation
physiologically acceptable
Prior art date
Application number
HR20030490A
Other languages
English (en)
Croatian (hr)
Inventor
Kroll Werner
Rombout Ferdinand
Weber Horst
Rodriguez Maria-Luisa
Sennhenn Bernd
Schohe-Loop Rudolf
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of HRP20030490A2 publication Critical patent/HRP20030490A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HR20030490A 2000-11-22 2001-11-09 Repinotan kit HRP20030490A2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10058119A DE10058119A1 (de) 2000-11-22 2000-11-22 Pepinotan-Kit
PCT/EP2001/012968 WO2002041881A2 (de) 2000-11-22 2001-11-09 Repinotan-kit

Publications (1)

Publication Number Publication Date
HRP20030490A2 true HRP20030490A2 (hr) 2005-06-30

Family

ID=7664358

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030490A HRP20030490A2 (hr) 2000-11-22 2001-11-09 Repinotan kit

Country Status (37)

Country Link
US (2) US6605255B2 (enExample)
EP (1) EP1339403B1 (enExample)
JP (2) JP2004517824A (enExample)
KR (1) KR20030096237A (enExample)
CN (2) CN1518446A (enExample)
AR (1) AR031761A1 (enExample)
AT (1) ATE284212T1 (enExample)
AU (1) AU2002227912A1 (enExample)
BG (1) BG107803A (enExample)
BR (1) BR0115518A (enExample)
CA (1) CA2429310A1 (enExample)
CZ (1) CZ20031401A3 (enExample)
DE (2) DE10058119A1 (enExample)
DO (1) DOP2001000293A (enExample)
EC (1) ECSP034617A (enExample)
EE (1) EE200300242A (enExample)
ES (1) ES2234922T3 (enExample)
GT (1) GT200100236A (enExample)
HN (1) HN2001000262A (enExample)
HR (1) HRP20030490A2 (enExample)
HU (1) HUP0303294A2 (enExample)
IL (1) IL155975A0 (enExample)
MA (1) MA26059A1 (enExample)
MX (1) MXPA03004499A (enExample)
MY (1) MY118345A (enExample)
NO (1) NO20032212D0 (enExample)
NZ (1) NZ525964A (enExample)
PE (1) PE20020533A1 (enExample)
PL (1) PL361628A1 (enExample)
PT (1) PT1339403E (enExample)
RU (1) RU2003118583A (enExample)
SI (1) SI1339403T1 (enExample)
SK (1) SK5922003A3 (enExample)
SV (1) SV2003000744A (enExample)
UY (1) UY27027A1 (enExample)
WO (1) WO2002041881A2 (enExample)
ZA (1) ZA200303888B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8329695B2 (en) * 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE19522088A1 (de) * 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19543476A1 (de) * 1995-11-22 1997-05-28 Troponwerke Gmbh & Co Kg Verwendung von substituierten Aminomethyl-chromanen zur Behandlung von Schädel-Hirn-Trauma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE19754573A1 (de) * 1997-12-09 1999-06-10 Bayer Ag Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma
EP1062510A2 (en) * 1998-03-10 2000-12-27 Strategic Diagnostics Inc. Integrated assay device and methods of production and use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19936281C2 (de) 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung

Also Published As

Publication number Publication date
ZA200303888B (en) 2004-05-20
UY27027A1 (es) 2002-07-31
EP1339403A2 (de) 2003-09-03
WO2002041881A2 (de) 2002-05-30
BR0115518A (pt) 2003-09-16
JP2005232189A (ja) 2005-09-02
MXPA03004499A (es) 2004-05-14
DE50104790D1 (de) 2005-01-13
DE10058119A1 (de) 2002-05-23
CN1518446A (zh) 2004-08-04
HN2001000262A (es) 2002-01-30
CN1715279A (zh) 2006-01-04
ATE284212T1 (de) 2004-12-15
MA26059A1 (fr) 2004-04-01
KR20030096237A (ko) 2003-12-24
WO2002041881A3 (de) 2002-10-10
NO20032212L (no) 2003-05-15
ECSP034617A (es) 2003-06-25
HUP0303294A2 (en) 2007-09-28
AU2002227912A1 (en) 2002-06-03
EE200300242A (et) 2003-10-15
GT200100236A (es) 2002-06-25
EP1339403B1 (de) 2004-12-08
US6605255B2 (en) 2003-08-12
CA2429310A1 (en) 2002-05-30
SK5922003A3 (en) 2003-11-04
PE20020533A1 (es) 2002-07-13
CZ20031401A3 (cs) 2003-10-15
AR031761A1 (es) 2003-10-01
US20030203953A1 (en) 2003-10-30
MY118345A (en) 2004-10-30
ES2234922T3 (es) 2005-07-01
NO20032212D0 (no) 2003-05-15
RU2003118583A (ru) 2004-12-20
PT1339403E (pt) 2005-03-31
JP2004517824A (ja) 2004-06-17
SV2003000744A (es) 2003-01-13
DOP2001000293A (es) 2002-03-15
NZ525964A (en) 2006-02-24
PL361628A1 (en) 2004-10-04
BG107803A (bg) 2004-01-30
SI1339403T1 (en) 2005-04-30
IL155975A0 (en) 2003-12-23
US20030060493A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
HRP20030490A2 (hr) Repinotan kit
Stangier et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers
Strong et al. Pharmacokinetics in man of the N-acetylated metabolite of proeainamide
Klotz et al. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide
CN103323592B (zh) 高通量毒品毒物快速检测芯片及系统
Anderson et al. Pemphigus and other diseases: Results of indirect intercellular immunofluorescence
AU2022314086A1 (en) Pharmaceutical composition containing anti-trop2 antibody drug conjugate and use thereof
Harrison et al. High-pressure liquid chromatographic determination of salicylsalicylic acid, aspirin, and salicylic acid in human plasma and urine
Dromgoole et al. Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis
Kunz et al. Bioavailability of escin after administration of two oral formulations containing aesculus extract
SAITA et al. A highly sensitive enzyme-linked immunosorbent assay (ELISA) for antitumor polyacetylenic alcohol, panaxytriol
US20250367311A1 (en) Pharmaceutical composition containing an antibody-drug conjugate and use thereof
YONG-CHENG et al. Production and characterization of anti-estrone monoclonal antibody
HK1068280A (en) Repinotan kit
PARKE Detection of prolactin activity by bioassay in human amniotic fluid
Lin et al. Pharmacokinetics and metabolism of rosaramicin in humans
Jun et al. Blood levels of chlorphentermine in man
US20250090565A1 (en) Compositions and Methods for Treating Bleeding and Bleeding Disorders
CN112557547B (zh) 用于测定氨甲苯酸冻干制剂体内行为的方法
Chaibva Development and Assessment of an Oxytocin Parenteral Dosage Form Prepared Using Pluronic® F127
Puri et al. The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent
Daigneault et al. Investigation of the Influence of Acetylsalicylic Acid on the Steady State of Long‐Term Therapy With Theophylline in Elderly Male Patients With Normal Renal Function
Wang et al. Assessment of Nutrition by Aneurin in Urine
Funro et al. A Highly Sensitive Enzyme-Linked Immunosorbent Assay (ELISA) for Antitumor Polyacetylenic Alcohol, Panaxytriol
US20240016822A1 (en) Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn